Relapse and Recovery

Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.

The immune system has an extraordinary ability to recognize compounds foreign to the body and eliminate them. NIDA-sponsored scientists are working to harness this ability to create vaccines that will protect individuals against the psychogenic and addictive effects of abused drugs. This animation shows one of the most promising strategies, which has already yielded partial success in producing effective vaccines against nicotine, cocaine, and other drugs.

In a new series of studies tracing the molecular events that occur in the brain as memories are formed and preserved, researchers find that certain epigenetic changes may promote vulnerability to relapse.

Reports on a new medication strategy under investigated in animal studies that shows promise for preventing relapse to drug abuse.

Summarizes a study to determine whether a stress-related biological marker in saliva can predict how long a drug user will remain in treatment.

Discusses the work of NIDA’s Division of Basic Neuroscience and Behavioral Research, the Institute’s locus for studies into the fundamental brain mechanisms underlying drug abuse and addiction.